Explore the full Peptides & GLP-1 library Independent editorial
(a) Gastrointestinal trials (Ulcerative Colitis) A Croatian research group conducted: A phase I safety study in healthy men A phase II trial of a rectal BPC-157 formulation for mildmoderate ulcerative colitis These are only available as abstracts and drug summaries , not as full peer-reviewed publications with methods, statistics, or adverse event profiles
About 27% were consistently adherent in year one (meaning they took the drug regularly), which fell to 17% in year two
Contributing Researchers Recognized for published work that shaped the scientific context discussed above Predrag Sikiri, MD, PhD authored foundational research on BPC-157 in cytoprotection research [2]
It should be used alongside a reduced-calorie diet and increased physical activity for best results
This triple receptor pathway interest separates it from single or dual agonist research compounds and makes it relevant in research environments where pathway comparison is important